Maintain 3-5% weight with anchored $85.55 decision-point stop, two-tranche add architecture, and 7% max exposure cap; Q2 FY27 earnings is binary re-evaluation catalyst.
HOLD at 3-5% with anchored $85.55 decision-point stop (not passive auto-exit), defined two-tranche add architecture (50 SMA reclaim at $89.46 OR breakdown basing below $84.50), 7% max exposure cap, retain 3.37% dividend carry, weekly re-evaluation cadence, and Q2 FY27 late October as mandatory binary re-evaluation with explicit bull/base/bear decision tree: Bull (organic >+7% AND margin >19.5% AND close >$89.50 with MACD positive) = add 15-20% toward Overweight; Base (organic +5-7% AND margin 18-19.5%) = maintain; Bear (organic <+5% OR margin <18% OR goodwill commentary OR close <$82 on volume >12M) = exit and downgrade to Sell.
| Position | Action |
|---|---|
| Current position | Maintain 3-5% portfolio weight |
| Confirmed close >$89.46 (50 SMA) on volume ≥80M followed by pullback to $88.50-$89.00 on declining volume | Scale to 6-7%; reset stop to $87.00 |
| Confirmed close <$84.50 on volume ≥90M followed by 3-5 day base at $82-$84 | Scale to 7-9%; reset stop to $81.00 |
| MDT closes below $85.55 on expanding volume | Re-evaluate to reduce to 2-3% pending Q2 print |
| Maximum exposure in either direction | Cap at 7% |
Medtronic's capitulation reversal at major long-term support, combined with 13.7x forward P/E, 3.37% defensive yield, and +41% Q1 FY27 EPS growth, creates a compelling asymmetric risk-reward in a hawkish macro environment that rewards low-beta income stocks.
| Indicator | Value | Signal |
|---|---|---|
| Close | $87.75 | neutral |
| 200 SMA | $86.98 | bullish |
| 50 SMA | $89.46 | bearish |
| 10 EMA | $87.48 | bullish |
| RSI (14) | 46.90 | neutral |
| MACD | -0.90 | neutral |
| MACD Histogram | -0.31 | bullish |
| Bollinger Lower Band | $84.34 | bullish |
| VWMA | $87.36 | bullish |
| Volume | 105.7M | bullish |
Support: 86.98 · 85.55 · 84.34 | Resistance: 89.46 · 93.4
MDT defended the 200 SMA at $86.98 with a high-volume reversal on Oct 8 (105.7M shares, ~2x prior day), closing $0.77 above support. Short-term momentum is recovering (10 EMA turning up, RSI bounced from 37.61 to 46.90, MACD histogram narrowing toward zero), but price remains $1.71 below the 50 SMA at $89.46, indicating the medium-term corrective trend has not been reclaimed. Two actionable setups are presented: aggressive entry at current levels with stop below $85.55 targeting $89.46, or conservative entry waiting for confirmed close above the 50 SMA.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close <$84.50 on volume ≥90M followed by 3-5 day base at $82-$84
Then: Scale to 7-9%; stop reset to $81.00
Q1 FY27 was a major inflection point, not 'no catalyst' — the bear's own report flags Q2 FY27 earnings as an upcoming catalyst
↩ rebuts: “Bear's 'no company-specific catalyst' argument”
EV: ~27.5% one-year total return (~24% upside to $108.97 fair value + 3.37% dividend yield) · concedes: TTM P/E of 21.6x does look rich at current earnings; Goodwill at 46% of assets is a legitimate accounting concern for any serial-acquirer; Net Debt of $26.4B and Debt/FCF of 4.9x represents meaningful leverage; Payout ratio rising toward 76%; Operating margin compressed slightly YoY in recent quarters; Tax rate volatility is noisy quarter-to-quarter
MDT is a bear trap at $87.75: the forward P/E looks cheap only if you ignore that TTM EPS was inflated by M&A and a tax reset; the Q1 beat was acquired not earned; the capitulation reversal candle is more likely distribution into dip-buyers than accumulation; and the macro backdrop of 96% no-cut probability is compressing multiples on long-duration med-tech cash flows while competitive threats across Diabetes, CRM, Spine, and EP accelerate.
· concedes: Grant the volume on the Oct 8 reversal day; Q1 FY27 revenue of $9.76B and EPS of $1.14 are real numbers; Underlying organic growth of 5-7% is 'solid'; The defensive sector rotation play is real—'when you're moving FROM cyclicals INTO defensives'; Low beta of 0.567 means smaller swings; The 3.37% yield is real; Hugo system is 'real but still in early commercialization'; Affera pulsed-field ablation is 'solid tech'; Micra leadless pacemakers are 'excellent technology'; Capitulation reversal day interpretation 'could also be distribution into dip-buyers' not necessarily accumulation; The 200 SMA holding by $0.77 means the breakdown test 'hasn't failed yet'; Wait for confirmed close above $89.46—'Confirm the 50 SMA reclaim. Confirm a higher low. Confirm a volume pattern that looks like accumulation, not just one capitulation session'
→ vs conservative: Macro concerns (zero Fed cuts, hawkish commentary, gold flash crash) are irrelevant—MDT is not a growth-duration story; 13.7x forward earnings, 3.37% yield, 0.567 beta mean it doesn't need multiple expansion or Fed pivots to work
→ vs neutral: 'Balanced risk-reward' with no catalyst until late October earnings is wrong—restructuring tailwinds already in motion ($72M vs $267M), diabetes franchise inflecting, FY26 revenue accelerating to +8.4%
→ vs conservative: 200 SMA overhead at $89.46, negative MACD, and price below medium-term resistance are not reasons to wait—high-reward traders position before confirmation; 'wait for confirmation' means paying 10% more later
→ vs conservative: Goodwill concentration at 46% is manageable given Medtronic operates in duopoly-heavy markets with high switching costs, $5.43B FCF, and 86% capital return ratio
→ vs neutral: 'Just watching' is the worst possible advice when capitulation volume is printing a reversal at long-term support with RSI recovering from oversold (37.6 to 46.9) and MACD histogram narrowing
Market Capitalization
$112.24B
TTM P/E
21.56x
Forward P/E
13.68x
PEG Ratio
1.54
Price/Book
2.24x
Dividend Yield
3.37%
Beta
0.567
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$90.05
200-Day MA
$88.48
FY26 Revenue
$36.36B
FY26 Gross Profit
$23.64B
FY26 Operating Income
$6.83B
FY26 Net Income
$4.80B
FY26 Diluted EPS
$3.73
FY26 Operating Margin
18.8%
FY26 EBITDA
$9.81B
FY26 Free Cash Flow
$5.43B
FY26 CapEx
$1.90B
FY26 Dividends Paid
$3.64B
FY26 Buybacks
$1.04B
FY26 Operating Cash Flow
$7.33B
Q1 FY27 Revenue
$9.76B
Q1 FY27 Diluted EPS
$1.14
Q1 FY27 Operating Income
$1.84B
Q1 FY27 Gross Margin
65.0%
Q1 FY27 Operating CF
$1.79B
Q1 FY27 FCF
$1.29B
Q1 FY27 Special Charges
$72M
TTM Revenue
$37.54B
TTM Gross Margin
65.3%
TTM Operating Margin
19.3%
TTM Net Margin
13.9%
TTM EBITDA Margin
27.7%
TTM EBITDA
$10.41B
TTM Net Income
$5.23B
TTM EPS
$4.07
Forward EPS
$6.41
ROE
10.6%
ROA
5.1%
Total Assets
$93.31B
Total Debt
$28.15B
Net Debt
$26.41B
Stockholders' Equity
$50.23B
Goodwill
$43.19B
Other Intangibles
$10.24B
Net Tangible Assets
-$3.19B
Cash & ST Investments
$8.82B
Working Capital
$12.59B
Current Ratio
2.07x
Debt-to-Equity
55.4%
Inventory
$6.22B
R&D Spending
$2.87B
Quarterly Dividend
$921M
Annual Dividend
$2.88
Payout Ratio
~76%
Capital Return Ratio
86%
Debt/FCF
~4.9x
Effective Tax Rate Q1 FY27
16.3%
Effective Tax Rate Q4 FY26
31.4%
Interest Expense
$186M/quarter
Non-US Revenue
~40%
Book Value Per Share
$39.24
FCF Yield
~4.8%
Q1 FY27 Business Acquisition
$1.16B
Strengths
Concerns
Medtronic trades at an attractive forward P/E of 13.68x with 58% earnings growth implied by analyst consensus, supported by accelerating revenue growth (FY26 +8.4%, Q1 FY27 +13.7% YoY) and a strong FCF profile ($5.43B annually). The 3.37% dividend yield with 23+ years of increases and low 0.567 beta make it a defensive mega-cap holding, though the $43.19B goodwill (46% of assets) representing years of serial M&A remains the primary risk variable. Rating: HOLD.
Macro: Hawkish macro shift with higher-for-longer rates regime priced in. Fed Governor Waller's rising-rates comments triggered cross-asset risk-off moves including gold/silver flash crash ($400 billion shed), falling gold futures on stronger dollar and high yields, and flat FTSE 100 with oil surge weighing on equities. Prediction markets assign 96% probability to zero Fed rate cuts in 2026, treating it as a hold-and-watch policy year—more hawkish than the soft-landing/easing narrative that dominated earlier in the year. FRED macro series unavailable (API not configured); macro view grounded in news flow and prediction markets.